AnaptysBio, Inc (ANAB) stock
ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30
$49.24+2.63 (+5.64%)
Close on Oct 19, 2026Market cap $2.28BP/E –Yield –
AnaptysBio free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
AnaptysBio's free cash flow for the twelve months ending Mar 31, 2026 was $4.41M. For fiscal 2025 it was $19.61M. The highest annual figure on record is $19.61M in fiscal 2025.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.61M | – |
| FY2024 | Dec 31, 2024 | -$135.70M | – |
| FY2023 | Dec 31, 2023 | -$121.61M | – |
| FY2022 | Dec 31, 2022 | -$73.95M | – |
| FY2021 | Dec 31, 2021 | -$47.29M | – |
| FY2020 | Dec 31, 2020 | -$14.73M | – |
| FY2019 | Dec 31, 2019 | -$70.32M | – |
| FY2018 | Dec 31, 2018 | -$49.57M | – |
| FY2017 | Dec 31, 2017 | -$19.73M | – |
| FY2016 | Dec 31, 2016 | -$9.08M | – |
| FY2015 | Dec 31, 2015 | -$9.93M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | -$25.94M | – |
| Q4 FY2025 | Dec 31, 2025 | $98.00M | – |
| Q3 FY2025 | Sep 30, 2025 | -$27.37M | – |
| Q2 FY2025 | Jun 30, 2025 | -$40.28M | – |
| Q1 FY2025 | Mar 31, 2025 | -$10.74M | – |
| Q4 FY2024 | Dec 31, 2024 | -$66.94M | – |
| Q3 FY2024 | Sep 30, 2024 | -$10.13M | – |
| Q2 FY2024 | Jun 30, 2024 | -$21.36M | – |
| Q1 FY2024 | Mar 31, 2024 | -$37.28M | – |
| Q4 FY2023 | Dec 31, 2023 | -$34.63M | – |
| Q3 FY2023 | Sep 30, 2023 | -$36.64M | – |
| Q2 FY2023 | Jun 30, 2023 | -$25.60M | – |
| Q1 FY2023 | Mar 31, 2023 | -$24.74M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.86M | – |
| Q3 FY2022 | Sep 30, 2022 | -$17.80M | – |
| Q2 FY2022 | Jun 30, 2022 | -$24.23M | -377.6% |
| Q1 FY2022 | Mar 31, 2022 | -$21.07M | – |
| Q4 FY2021 | Dec 31, 2021 | -$25.32M | -167.9% |
| Q3 FY2021 | Sep 30, 2021 | -$7.18M | – |
| Q2 FY2021 | Jun 30, 2021 | $8.73M | – |
| Q1 FY2021 | Mar 31, 2021 | -$23.52M | – |
| Q4 FY2020 | Dec 31, 2020 | $37.27M | – |
| Q3 FY2020 | Sep 30, 2020 | -$17.10M | – |
| Q2 FY2020 | Jun 30, 2020 | -$19.69M | – |
| Q1 FY2020 | Mar 31, 2020 | -$15.20M | – |
| Q4 FY2019 | Dec 31, 2019 | -$15.91M | – |
| Q3 FY2019 | Sep 30, 2019 | -$22.38M | – |
| Q2 FY2019 | Jun 30, 2019 | -$15.76M | – |
| Q1 FY2019 | Mar 31, 2019 | -$16.28M | – |
| Q4 FY2018 | Dec 31, 2018 | -$12.50M | – |
| Q3 FY2018 | Sep 30, 2018 | -$15.18M | – |
| Q2 FY2018 | Jun 30, 2018 | -$9.18M | – |
| Q1 FY2018 | Mar 31, 2018 | -$12.71M | – |
| Q4 FY2017 | Dec 31, 2017 | -$4.93M | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.90M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.71M | – |
| Q1 FY2017 | Mar 31, 2017 | -$8.18M | – |
| Q4 FY2016 | Dec 31, 2016 | -$5.57M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.07M | – |
See a number that looks wrong?